The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).

Guerini, V; Barbui, V; Spinelli, O; Salvi, A; Dellacasa, C; Carobbio, A; Introna, M; Barbui, T; Golay, J; Rambaldi, A

Guerini, V; Barbui, V; Spinelli, O; Salvi, A; Dellacasa, C; Carobbio, A; Introna, M; Barbui, T; Golay, J; Rambaldi, A.

Affiliation

Guerini V; Hematology Unit, Ospedali Riuniti, Bergamo, Italy.

Leukemia ; 22(4): 740-7, 2008 Apr.

Article in En | MEDLINE | ID: mdl-18079739

Subject(s)

Histone Deacetylase Inhibitors; Hydroxamic Acids/pharmacology; Janus Kinase 2/genetics; Polycythemia Vera/drug therapy; Thrombocythemia, Essential/drug therapy; Cell Line, Tumor; Cell Proliferation/drug effects; Down-Regulation/drug effects; Drug Delivery Systems; Humans; Janus Kinase 2/analysis; Mutation, Missense; Polycythemia Vera/pathology; STAT Transcription Factors/analysis; Thrombocythemia, Essential/pathology; Tumor Cells, Cultured

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Polycythemia Vera / Janus Kinase 2 / Histone Deacetylase Inhibitors / Thrombocythemia, Essential / Hydroxamic Acids Limits: Humans Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2008 Document type: Article Affiliation country: Italy

Search on Google

Add to My VHL

XML

PubMed Links